Vaxart Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Steven Lo

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure3yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Nov 16
Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20
There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15
An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Nov 08
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Jun 30
Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Sep 09

Ray Stapleton joins Vaxart as CTO

Aug 31

Vaxart shareholders approve proposal to increase number of shares

Aug 05

Vaxart continues to lobby shareholders to vote to increase number of shares

Jul 29

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program

Oct 30

CEO

Steven Lo (57 yo)

less than a year

Tenure

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. He has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive...


Leadership Team

NamePositionTenureCompensationOwnership
Sean Tucker
Senior VP & Chief Scientific Officer14.8yrsUS$1.14m0.10%
$ 145.0k
James Cummings
Chief Medical Officer3.3yrsUS$1.17m0.063%
$ 88.2k
Steven Lo
Presidentless than a yearno datano data
Phillip Eric Lee
CFO, Principal Financial Officer & Principal Accounting Officer1.9yrsno data0.036%
$ 49.8k
Raymond Stapleton
Chief Technology Officer2.3yrsno datano data
Edward Berg
Senior VP & General Counsel2.8yrsno data0.050%
$ 69.3k
Shaily Garg
Senior Vice President of Clinical Development & Project Management4.7yrsno datano data
Rajesh Kapoor
Senior Vice President of Quality3.8yrsno datano data

3.0yrs

Average Tenure

56.5yo

Average Age

Experienced Management: VXRT's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Steven Lo
Presidentless than a yearno datano data
Robert Yedid
Independent Director5.1yrsUS$92.26k0.0081%
$ 11.3k
Harry Greenberg
Member of Scientific & Clinical Advisory Board3.3yrsno datano data
Elaine Heron
Independent Director2.3yrsUS$89.08k0.011%
$ 15.0k
Michael Finney
Independent Chairman of the Board6.8yrsUS$109.57k0.29%
$ 410.6k
Stefan Gravenstein
Member of Scientific & Clinical Advisory Board3.3yrsno datano data
David Wheadon
Independent Director3.6yrsUS$93.72k0.0065%
$ 9.0k
Robert Belshe
Member of Scientific & Clinical Advisory Board3.3yrsno datano data
William Watson
Independent Director2.3yrsUS$94.76k0.023%
$ 32.0k
Marion Pepper
Member of Scientific & Clinical Advisory Board3.3yrsno datano data
Ralph Baric
Member of Scientific & Clinical Advisory Board3.3yrsno datano data
Gregory Gray
Member of Scientific & Clinical Advisory Board3.3yrsno datano data

3.3yrs

Average Tenure

66yo

Average Age

Experienced Board: VXRT's board of directors are considered experienced (3.3 years average tenure).